Drug profile · INN
covid-19 vaccine (recombinant, adjuvanted)
BIMERVAX
covid-19 vaccine (recombinant, adjuvanted) (BIMERVAX) is a spike glycoprotein vaccine antigen.
EMA: approved Antiinfectives for systemic use (J07) J07BN
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — covid-19 vaccine (recombinant, adjuvanted)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.83
Quick answer
covid-19 vaccine (recombinant, adjuvanted) (BIMERVAX) is a spike glycoprotein vaccine antigen.
Key facts
INN covid-19 vaccine (recombinant, adjuvanted)
Brand BIMERVAX
Mechanism Spike glycoprotein vaccine antigen
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BN
Mechanism of action
Spike glycoprotein vaccine antigen
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is covid-19 vaccine (recombinant, adjuvanted)?
covid-19 vaccine (recombinant, adjuvanted) (BIMERVAX) is a spike glycoprotein vaccine antigen.
What is the brand name for covid-19 vaccine (recombinant, adjuvanted)?
BIMERVAX is a marketed brand name for covid-19 vaccine (recombinant, adjuvanted). Check FDA Drugs@FDA for the current US label holder and prescribing information.